Table 6. The relationship between mRNA expression of EZH2 and SMYD3 and clinicopathological features.

Pathological characteristics	Case	EZH2 mRNA expression	P	SMYD3 mRNA expression	P
Age (years)			0.623		0.206
≥40	591	1.66 ± 0.20		1.13 ± 0.16
<40	121	1.67 ± 0.22		1.15 ± 0.15
Age of menarche (years)			0.553		0.999
≥13	495	1.66 ± 0.21		1.13 ± 0.15
<13	217	1.67 ± 0.20		1.13 ± 0.17
Menopausal status			0.677		0.113
Premenopause	81	1.67 ± 0.23		1.16 ± 0.16
Postmenopause	631	1.66 ± 0.20		1.13 ± 0.16
Tumor size (cm)			0.372		0.197
≤2.0	323	1.67 ± 0.19		1.14 ± 0.16
2.1–4	329	1.66 ± 0.22		1.13 ± 0.16
>4	60	1.63 ± 0.20		1.10 ± 0.16
Pathological type			0.368		0.779
IDC	618	1.66 ± 0.20		1.13 ± 0.15
ILC	31	1.66 ± 0.20		1.15 ± 0.15
Other	63	1.66 ± 0.23		1.13 ± 0.19
Lymph node metastasis			<0.001		<0.001
Negative	335	1.61 ± 0.19		1.09 ± 0.14
Positive	377	1.71 ± 0.21		1.17 ± 0.17
Immunohistochemical indexes			0.392		0.433
ER (−)	176	1.66 ± 0.21		1.15 ± 0.15
ER (+)	536	1.66 ± 0.21		1.13 ± 0.16
PR (−)	168	1.66 ± 0.21		1.14 ± 0.15
PR (+)	544	1.66 ± 0.20		1.13 ± 0.16
HER2 status			<0.001		<0.001
Negative	361	1.62 ± 0.18		1.10 ± 0.14
Positive	351	1.71 ± 0.22		1.16 ± 0.17
FDRs with breast cancer			0.531		0.426
Yes	251	1.67 ± 0.21		1.14 ± 0.16
No	461	1.66 ± 0.20		1.13 ± 0.16
Clinical staging			0.004		0.154
I/II	654	1.66 ± 0.20		1.13 ± 0.15
III/IV	58	1.74 ± 0.25		1.16 ± 0.19
Subtypes of breast cancer			<0.001		<0.001
Triple negative	133	1.74 ± 0.25		1.18 ± 0.17
Non-triple negative	579	1.65 ± 0.19		1.12 ± 0.15
Metastasis situation			<0.001		<0.001
Distant metastasis	154	1.74 ± 0.21		1.19 ± 0.19
Primary lesion	558	1.64 ± 0.20		1.12 ± 0.14

Abbreviations: IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.